{"classes":[{"categories":[{"measurements":[{"comment":"Upper 95%CI not reached due to end of study monitoring duration","groupId":"OG000","lowerLimit":"286","upperLimit":"NA","value":"717"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"PFS measured from ASCT to time of myeloma progression (as defined by the International Myeloma Working Group \\[IMW\\] consensus criteria or subject death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Galinpepimut-S (GPS) vaccinations are started 12-22 days following autologous stem cell transplantation (ASCT). GPS and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants whose disease has not progressed and who are clinically stable (no active infection with fevers and no cardiovascular/respiratory compromise) may receive up to 6 additional monthly vaccinations. The use of post-ASCT maintenance therapy is allowed starting 3 months after ASCT.\n\nGalinpepimut-S: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule\n\nGM-CSF: subcutaneous injection\n\nMontanide: adjuvant\n\nlenalidomide: optional post-ASCT therapy\n\nbortezomib: optional post-ASCT therapy","id":"OG000","title":"Galinpepimut-S + Montanide + GM-CSF"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"3 years and 8 months","title":"Progression-free Survival (PFS) From Autologous Stem Cell Transplant (ASCT)","type":"SECONDARY","unitOfMeasure":"days"}